Successfully enrolled and ready to begin the VDOP program not on insulin therapy
Type 2 diabetes by clinical history
HbA1C between 8.0-12.0% inclusive within 3 months of enrollment
Assessment by clinician that patient is willing to and able to wear a CGM device
Stable diabetes medication regimen during the 3 months prior to entry
You may not be if
Patients already or planned on starting insulin therapy, already on CGM, or those who qualify for CGM under VA policy
Patients with gestational diabetes or pregnant at time of screening or are planning to become pregnant during the study
Patients with end stage renal disease (ESRD) on dialysis
Anticipated acute uses of glucocorticoids (oral, injectable, or IV)
Acute conditions that impact the HbA1c measurement stability such as GI blood loss, recent (within 3 months of study entry), anticipated red blood cell transfusion or erythropoietin administration
Known or suspected significant allergy to use the Dexcom sensors
Planning or currently enrolled on different weight program different from MOVE!
